Communication orales LYSA | ASCO 2020 |
---|---|
C Herbaux | Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA
|
S Le Gouill |
Communication orales LYSA | ASCO 2020 |
---|---|
C Herbaux | Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA
|
S Le Gouill |